Danish pharmaceutical giant Novo Nordisk is showcasing 17 innovative drugs and four novel injection devices at the #
CIIE2026#. Highlights include Kyinsu®, the world’s first once-weekly fixed-dose combination therapy for adults with type 2 diabetes, approved in China, and the Wegovy® pill, the world’s first approved oral GLP-1 treatment for weight management.
@novonordisk